The latest Investing Matters Podcast episode has just been released with Asif Suria, Founder & Editor of Inside Arbitrage. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.90
Bid: 12.80
Ask: 13.00
Change: -0.25 (-1.90%)
Spread: 0.20 (1.562%)
Open: 13.15
High: 13.15
Low: 12.80
Prev. Close: 13.15
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Kingswood cuts outlook; Poolbeg in patent joy

Mon, 02nd Oct 2023 14:20

(Alliance News) - The following is a round-up of updates by London-listed companies, issued last week and not separately reported by Alliance News:

----------

Kingswood Holdings Ltd - wealth manager - Cuts profit guidance. Kingswood's revenue in the half-year ended June 30 declines 22% to GBP80.4 million from GBP62.7 million and its pretax loss widens to GBP9.9 million from GBP1.7 million. Kingswood cuts its proforma operating profit guidance to GBP13.6 million from GBP14.7 million, due to lower than expected investment banking and capital markets activity.

----------

Poolbeg Pharma PLC - London-based infectious disease focused biopharmaceutical company - Says hearing with European Patent Office related to Immunomodulator I, one of its European patents, has been cancelled. "This favourably concludes this matter with the patent maintained as granted," Poolbeg adds.

----------

PHSC PLC - Kent-based health, safety, hygiene and environmental consultancy services provider - Says revenue for five-months ended August 31 falls to just shy of GBP1.4 million from GBP1.4 million a year prior. Earnings before interest, tax, depreciation, and amortisation down to GBP139,000, from GBP144,000. "This was caused by the lower revenues not being fully offset by reduced costs and the pay increases referred to above," PHSC says.

----------

Looking Glass Labs Ltd - specialises in metaverse, play-to-earn tokenisation and blockchain monetisation - Plans share consolidation. Every 75 shares to be consolidated into one share.

----------

Grand Vision Media Holdings PLC - out-of-home advertising and digital marketing company - Revenue in six months to June rises 21% to HKD2.3 million, around GBP237,829, from HKD1.9 million a year prior. Pretax loss narrows to HKD2.0 million from HKD2.3 million. Company says: "After the 3-year period shroud by Covid-19, the world enters a new post-pandemic era in 2023. However, the general market outlook continue to present many challenges due to tightening economic conditions in China and other global economies. We continue to diversify and look for new revenue streams and business models to augment our core marketing services. The new initiative of international brand management and expansion whereby we help brands expand to new geographies is progressing and we expect to generate revenue from this in the second half of the year. In particular, we will be working closely with our Korean and Thai customers to increase cross-border ecommerce."

----------

KR1 PLC - investor focused on the blockchain industry - Net asset value per share rises 67% year-on-year to 51.1 pence per share at its June 30 half-year end. NAV per share is 30% higher from December 31. "With some positive market momentum as well as major new investments that were announced since the year-end, the company's net assets have grown substantially to GBP90.7 million at the end of June, providing shareholders with capital growth, which remains our main long-term focus. The year-on-year decline in income from digital assets, driven by various factors, including stagnant prices over the relevant period, was expected, while still being of great benefit to the company."

----------

VVV Resources Ltd - investor focused on identifying opportunities in the precious metals and base metals sector - Pretax loss in half-year to June 30 narrows to GBP62,000 from GBP77,000 a year prior. Loss is solely down to administrative costs, which decline 19% to GBP62,000. Posts no revenue, unchanged from prior year.

----------

Octopus Titan VCT PLC - venture capital trust - Says will raise maximum of GBP125 million, with an over-allotment facility worth GBP75 million, in planned offer for subscription.

----------

One Heritage Group PLC - UK-based residential developer focused on the north of England - Completes sale of remaining 15 units at Lincoln House, Bolton, ahead of updated deadline of October 9. "The funds have been received in full, including an interest payment that the buyer had to pay," it says. In addition, One Heritage says Anthony Unsworth resigns as chief financial officer. One Heritage adds: "Anthony will continue in his role as CFO and executive director during his notice period during the next six months. The company has already begun speaking with its contacts in the headhunter world and has started the process of finding the right person for the next leg of the growth in the business."

----------

Cavendish Financial PLC - London-based stockbroker - Says trading in the City was "quiet during the summer", though Cavendish, established on September 8 via the merger of finnCap and Cenkos, has been busy since forming. Cavendish Financial adds: "Since merger completion the group has already announced a number of significant transactions which will close in the coming months including acting as sole adviser to Round Hill Royalty Fund Ltd on its offer from Concord Cadence Ltd, fundraisings for Haydale Graphene PLC and Shield Therapeutics plc and obtaining key regulatory clearances for the equity financing of Allergy Therapeutics by ZQ Capital and Southern Fox."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
6 Jun 2024 14:52

UK shareholder meetings calendar - next 7 days

Friday 7 June 
Property Franchise Group PLCAGM
Trident Royalties PLCAGM
TruSpine Technologies PLCAGM
Monday 10 June 
Aterian PLCAGM
Griffin Mining LtdAGM
Lok'n Store Group PLCGM re takeover by Shurgard
Onward Opportunities LtdAGM
Oxford Nanopore Technologies PLCAGM
Pan African Resources PLCGM re capital reduction
Tuesday 11 June 
Ebiquity PLCAGM
Flowtech Fluidpower PLCAGM
MaxCyte IncAGM
Mobico Group PLCAGM
Newbury Racecourse PLCAGM
Nightcap PLCGM re fundraise
Phoenix Digital Assets PLCGM re up to GBP33.7 million fundraise
Tirupati Graphite PLCGM requisitioned by Walpole St Andrews Nominees
Tortilla Mexican Grill PLCAGM
Tufton Oceanic Assets LtdEGM
Wednesday 12 June 
Advanced Medical Solutions Group PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Aurora Investment Trust PLCAGM
BioPharma Credit PLCAGM
Brighton Pier Group PLCAGM
Digital 9 Infrastructure PLCAGM
EPE Special Opportunities LtdAGM
Foresight Solar Fund LtdAGM
Star Energy Group PLCAGM
Thursday 13 June 
Beacon Rise Holdings PLCAGM
Christie Group PLCAGM
Everyman Media Group PLCAGM
Hochschild Mining PLCAGM
Iofina PLCAGM
Jadestone Energy PLCAGM
Panther Metals PLCAGM
Pollen Street Group LtdAGM
Poolbeg Pharma PLCAGM
Serabi Gold PLCAGM
Smurfit Kappa Group PLCGM re WestRock deal
Sound Energy PLCAGM
Starwood European Real Estate Finance LtdAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
1 May 2024 16:39

Poolbeg Pharma celebrates full patent approval for Immunomodulator II

(Alliance News) - Poolbeg Pharma PLC on Wednesday said that it has received a fully granted patent from the US Patent Office for its Immunomodulator II patent application.

Read more
30 Apr 2024 16:43

Poolbeg agrees 12-month option over potential Behcet's treatment

(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX).

Read more
30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Mar 2024 11:10

Poolbeg Pharma to be granted US patent

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

Read more
19 Feb 2024 14:22

Director dealings: Poolbeg Pharma co-founder ups stake

(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.

Read more
15 Feb 2024 16:02

TRADING UPDATES: Diversified Energy offers dividend alternative

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
12 Feb 2024 19:44

TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
12 Feb 2024 14:37

Poolbeg upbeat on research into potential drug market

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.

Read more
17 Jan 2024 13:58

Poolbeg Pharma hails POLB 001'S potential to treat CRS

(Alliance News) - Poolbeg Pharma PLC on Wednesday noted "promising" results for POLB 001's potential in treating cancer immunotherapy-induced cytokine release syndrome.

Read more
20 Dec 2023 20:00

TRADING UPDATES: K3 Business says cash balances ahead of forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Dec 2023 13:54

Poolbeg makes promising progress with RSV programme

(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

Read more
21 Nov 2023 14:39

TRADING UPDATES: Poolbeg hails approval; EDX links with Thermo Fisher

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
9 Nov 2023 16:57

IN BRIEF: Poolbeg Pharma appoints former Amryt executives to team

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.